Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
STS Inhibitor
Steroid Sulfatase-IN-2 is a potent steroid sulfatase (STS) inhibitor, exhibiting an IC50 value of 109.5 nM. This compound enables research into hormone-dependent cancers, particularly those driven by estrogen, such as breast and endometrial cancer. Its role as an STS inhibitor makes it a valuable tool for understanding the molecular mechanisms underlying these cancer types and exploring potential therapeutic strategies. -
STS Inhibitor
Steroid sulfatase-IN-8 is a potent steroid sulfatase (STS) inhibitor, demonstrating a pharmacological IC50 of 1 nM in PM models and 0.025 nM in JEG-3 cells. This compound effectively interferes with steroid metabolism, making it a valuable tool for investigating steroid-related pathways. Its application extends to studies on hormone-dependent cancers and other conditions linked to altered steroid levels. -
Steroid Sulfatase Inhibitor
DU-14 is a potent inhibitor of steroid sulfatase, exhibiting an IC50 of 55.8 nM. It effectively reduces MCF-7 cell proliferation, with an IC50 value of 38.7 nM. Additionally, DU-14 demonstrates neuroprotective properties against neurotoxic amyloid-beta (Aβ), indicating its potential to up-regulate endogenous dehydroepiandrosterone sulfate (DHEAS) and alleviate Aβ-induced deficits in spatial memory and synaptic plasticity. This compound is valuable for research in cancer biology and neurodegenerative diseases. -
STS Inhibitor
Steroid sulfatase-IN-4 is an irreversible inhibitor of steroid sulfatase (STS), exhibiting an IC50 of 25 nM against human STS. This compound is primarily utilized in research focused on endometriosis, offering potential insights into the role of STS in disease progression and therapeutic interventions. Its selective inhibition of STS facilitates the exploration of hormonal pathways involved in reproductive health. -
STS Inhibitor
Steroid sulfatase-IN-3 is a potent inhibitor of steroid sulfatase (STS) with an IC50 value of 25.8 nM. This compound exhibits significant antiproliferative activity against T-47D estrogen-dependent breast cancer cells, demonstrating an IC50 of 1.04 µM. Steroid sulfatase-IN-3 is primarily utilized in cancer research to explore the role of STS in hormone-dependent tumor progression and treatment resistance. -
Steroid Sulfatase Inhibitor
Steroid sulfatase-IN-1 is a highly effective inhibitor of steroid sulfatase, exhibiting an IC50 value of 1.71 nM. This compound demonstrates significant antitumor activity in vivo, indicating its potential utility in cancer research. Steroid sulfatase-IN-1 is particularly relevant for studies focused on breast cancer, providing insights into mechanisms of disease and potential therapeutic approaches. -
Steroid sulfatase/17β-HSD1 Inhibitor
Steroid sulfatase/17β-HSD1-IN-1 is a potent inhibitor of steroid sulfatase and 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), exhibiting an IC50 value of 28 nM for human steroid sulfatase in cellular assays. This compound is valuable for investigating estrogen-dependent diseases, making it an important tool for research in hormone-related therapeutic areas. Its specificity and potency support studies aiming to elucidate the role of these enzymes in disease mechanisms. -
Steroid sulfatase/17β-HSD1 Inhibitor
Steroid sulfatase/17β-HSD1-IN-4 is a potent dual inhibitor of steroid sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1 (17β HSD1). It irreversibly inhibits hSTS activity, demonstrating an IC50 value of 63 nM. This compound is valuable for studying endometriosis and other estrogen-dependent diseases, providing insights into the role of steroid metabolism in these conditions. -
Steroid Sulfatase Inhibitor
Steroid sulfatase-IN-11 is a potent inhibitor of steroid sulfatase, an enzyme that hydrolyzes steroid sulfates. By effectively reducing steroid sulfatase activity, this compound is instrumental in the study of hormone-dependent cancers. Its application in research provides valuable insights into the role of steroid metabolism in cancer progression and therapeutic resistance. -
Succinate Dehydrogenase Inhibitor
Flubeneteram is an inhibitor of succinate dehydrogenase, exhibiting an IC50 value of 0.0484 μM. This compound effectively disrupts the activity of succinate dehydrogenase, contributing to its biological activity. Flubeneteram has demonstrated protective effects against fungal pathogens such as Rhizoctonia solani and Sphaerotheca fuliginea in preclinical studies. It is a valuable reagent for research focused on fungal infection mechanisms and potential therapeutic strategies. -
TrxR Inhibitor
Ethaselen is a selective thioredoxin reductase (TrxR) inhibitor known for its potent inhibitory action, with IC50 values of 0.5 μM for wild-type human TrxR1 and 0.35 μM for rat TrxR1. This organoselenium compound specifically targets the unique selenocysteine-cysteine redox pair in the C-terminal active site of mammalian TrxR1. Ethaselen demonstrates significant antitumor activity, particularly against non-small cell lung cancer (NSCLC), making it a promising candidate for cancer research applications focused on apoptosis and redox regulation. -
TrxR1 Inhibitor
DVD-445 is a potent peptidomimetic inhibitor of thioredoxin reductase 1 (TrxR1), exhibiting an IC50 value of 0.60 μM against rat TrxR1. This compound demonstrates significant anticancer activity, making it a valuable tool for research applications focused on cancer biology and oxidative stress mechanisms. Its ability to interact covalently with TrxR1 positions DVD-445 as an important reagent for exploring therapeutic strategies targeting oxidative stress in cancer cells. -
TrxR Inhibitor
TrxR-IN-2 is a selective inhibitor of thioredoxin reductase (TrxR), a critical enzyme involved in redox regulation. This compound demonstrates significant inhibitory activity in various cancer models, particularly in drug-resistant hepatocellular carcinoma. TrxR-IN-2 is suitable for research applications focused on understanding TrxR's role in cancer biology and exploring potential therapeutic strategies against aggressive tumor types. -
Trx/TrxR System Inhibitor
PMX464 is a thiol-reactive quinol that acts as an inhibitor of the thioredoxin-thioredoxin reductase (Trx/TrxR) system. This compound has been shown to inhibit NF-κB-mediated pro-inflammatory activation in human type II alveolar epithelial cells, making it a valuable tool for research focused on inflammation and oxidative stress. PMX464 is particularly useful in studies examining the role of redox signaling in various pathophysiological conditions. -
TrxR Inhibitor
TrxR-IN-3 is a potent inhibitor of thioredoxin reductase (TrxR), exhibiting significant antiproliferative activity against various human cancer cell lines, particularly breast cancer cells. This compound enhances reactive oxygen species (ROS) levels, leading to apoptosis through the modulation of apoptosis-related proteins. Additionally, TrxR-IN-3 promotes autophagy by increasing the expression of LC3-II and Beclin-1 while reducing levels of LC3-I and p62, facilitating the formation of autophagosomes and autolysosomes. This makes TrxR-IN-3 a valuable tool for studying the mechanisms of cancer cell death and autophagy. -
TrxR1 Inhibitor
TrxR1-IN-1 is a selective inhibitor of thioredoxin reductase 1 (TrxR1), exhibiting an IC50 of 8.8 μM. This compound demonstrates significant anticancer activity, achieving IC50 values of 1.5 μM in MCF-7 cells, 1.7 μM in HeLa cells, 2.4 μM in BGC-823 cells, 2.8 μM in SW-480 cells, and 2.1 μM in A549 cells. Additionally, TrxR1-IN-1 possesses antioxidant properties and effectively scavenges DPPH radicals, making it a valuable tool for research in cancer biology and oxidative stress studies. -
TrxR Inhibitor
TrxR-IN-4 is a potent inhibitor of thioredoxin reductase (TrxR), demonstrating significant biological activity by inducing apoptosis in HepG2 cells via the activation of endoplasmic reticulum stress (ERS). This compound also exhibits protective effects against CCl4-induced liver damage in vivo, achieved through the down-regulation of TrxR expression and inflammatory responses. TrxR-IN-4 is a valuable tool for researching the modulation of oxidative stress and cancer therapies. -
TrxR Inhibitor
CPUL1 is a selective inhibitor of thioredoxin reductase (TrxR), demonstrating significant anti-proliferative and anti-metastatic effects in A549 lung cancer cells. It modulates epithelial-mesenchymal transition (EMT) through the induction of reactive oxygen species (ROS) and activation of ERK/JNK signaling pathways resulting from the inhibition of TrxR1 enzyme activity. CPUL1 exhibits enhanced efficacy when used in combination with α-Lipoic Acid or Dithiodipropionic acid, making it a valuable tool for cancer research and therapeutic strategies. -
Tyrosinase Inhibitor
Methyl rosmarinate is a noncompetitive inhibitor of tyrosinase, effectively isolated from Rabdosia serra, with an IC50 value of 0.28 mM for mushroom tyrosinase. Additionally, it demonstrates inhibitory activity against α-glucosidase. This compound is valuable for research in pigmentation, skin disorders, and carbohydrate metabolism. -
PPO Inhibitor
2,3-Diaminopropionic acid hydrochloride acts as an inhibitor of polyphenol oxidase (PPO), an enzyme involved in the browning reaction of fruits and vegetables. This compound serves as a key precursor for the synthesis of antibiotics and the siderophore staphyloferrin B. Its ability to modulate PPO activity makes it valuable for research in enzymology and agriculture, particularly in studies aimed at controlling oxidative processes in various biological systems. -
XO Inhibitor
Procyanidin B2 3′-O-gallate is a potent inhibitor of xanthine oxidase (XO), exhibiting an IC50 of 24.24 μM and a Ki value of 6.16 μM. Its notable antioxidant activity allows for the reduction of UV-induced α-tocopheroxyl formation. This compound is suitable for research related to hyperuricemia and gout, providing a valuable tool for investigating therapeutic strategies in these conditions. -
DAAO Inhibitor
Luvadaxistat is a highly selective and potent inhibitor of D-amino acid oxidase (DAAO), demonstrating an IC50 value of 14 nM in the inhibition of oxidative deamination of D-serine. This compound significantly elevates D-serine concentrations in various biological matrices, including the rodent brain, plasma, and cerebrospinal fluid. Luvadaxistat holds promise as a valuable tool for research into schizophrenia and related neurobiological disorders. -
HDX Inhibitor
2-Methylacetophenone is a potent xanthine dehydrogenase (XDH) inhibitor that competently interacts with the XDH active site, effectively preventing the conversion of xanthine to uric acid. This compound is instrumental in research applications focused on hyperuricemia and conditions related to elevated uric acid levels. Its use can deepen the understanding of purine metabolism and contribute to the development of therapeutic strategies. -
Xanthine Oxidase Inhibitor
Tigulixostat is a selective xanthine oxidase inhibitor with potent activity, demonstrating IC50 values of 0.003 µM in bovine milk and 0.073 µM in rat plasma. This compound effectively lowers serum uric acid levels and is utilized in research focusing on gout and hyperuricemia. Its oral bioavailability and targeted mechanism make it a valuable tool in studying these conditions. -
XOD Inhibitor
7,8,3′,4′-Tetrahydroxyflavone is a potent inhibitor of xanthine oxidase (XOD) with an IC50 value of 10.488 µM. This compound demonstrates significant inhibitory activity, making it a valuable tool for studies related to oxidative stress and purine metabolism. Research applications include investigating its potential therapeutic effects in conditions associated with hyperuricemia and gout. -
Xanthine Oxidase Inhibitor
8-Azaadenine is a potent inhibitor of xanthine oxidase, exhibiting an IC50 value of 0.54 μM and a Ki of 0.66 μM. This compound can be synthesized through the metabolism of 8-Azaadenosine and is capable of integrating into polynucleotide chains alongside 8-Azaguanine, thereby influencing purine metabolism. 8-Azaadenine serves as a valuable tool in cancer research, enabling investigations into therapeutic strategies targeting purine biosynthesis pathways. -
DAO Inhibitor
DAO-IN-1 is a potent inhibitor of D-amino acid oxidase (DAO), exhibiting an IC50 value of 269 nM. By inhibiting DAO, it effectively modulates D-serine levels, a crucial co-agonist of NMDA receptors. This compound is valuable for research investigating the roles of D-serine and NMDA receptor modulation in various neurological disorders. -
XO Inhibitor
Myricetin 3-O-galactoside is a potent xanthine oxidase (XO) inhibitor known for its antioxidant properties. It effectively reduces lipid peroxidation, exhibiting an IC50 value of 160 μg/mL. This compound is valuable for research applications focused on oxidative stress and related pathologies, providing insight into therapeutic approaches targeting reactive oxygen species. -
Xanthine Oxidase Inhibitor
O-Desisobutyl-O-n-propyl Febuxostat is an xanthine oxidase inhibitor that plays a crucial role in the modulation of uric acid levels. Its primary mechanism involves the inhibition of xanthine oxidase activity, which can be beneficial in the treatment of gout and hyperuricemia. This compound is valuable for research applications focused on purine metabolism, oxidative stress, and related metabolic disorders. Scientists can utilize it to explore therapeutic strategies targeting inflammatory pathways associated with elevated uric acid. -
XOR Inhibitor
Niraxostat is an orally active xanthine oxidoreductase (XOR) inhibitor. It is utilized in research focused on hyperuricemia and related pathologies where XOR plays a significant role in disease mechanisms. By inhibiting XOR, Niraxostat can help elucidate the biochemical pathways involved in uric acid metabolism and its associated conditions. -
Xanthine Oxidase Inhibitor
Azacosterol, a potent xanthine oxidase inhibitor, is known for its role as a DHCR24 inhibitor. This compound facilitates a series of biochemical reactions in cortical neurons, contributing to its significance in neurological research. Its unique mechanism positions it as a valuable tool in studies investigating oxidative stress and related pathways in various biological contexts. -
XO Inhibitor
Febuxostat sodium is a selective non-purine xanthine oxidase (XO) inhibitor, exhibiting a potent Ki value of 0.6 nM. It is primarily utilized in the investigation of hyperuricemia and gout due to its ability to effectively lower urate levels. This compound serves as a valuable tool for studying the biochemical pathways associated with purine metabolism and the therapeutic effects in gout-related conditions. -
XO Inhibitor
Xanthine oxidase-IN-7 is a potent xanthine oxidase (XO) inhibitor with an IC50 of 0.36 µM. It effectively lowers serum uric acid levels, making it a valuable tool for studying hyperuricemia and gout. This compound has significant potential in research applications focused on disorders related to uric acid metabolism. -
Xanthine Oxidoreductase Inhibitor
Xanthine oxidoreductase-IN-5 is a potent inhibitor of xanthine oxidoreductase (XOR), exhibiting an IC50 of 55 nM. This compound is employed in research focused on acute hyperuricemia, facilitating the investigation of uric acid metabolism and its associated disorders. Xanthine oxidoreductase-IN-5 serves as a valuable tool for exploring therapeutic strategies aimed at managing conditions related to elevated uric acid levels. -
XOR Inhibitor
Xanthine oxidoreductase-IN-2 is a potent inhibitor of xanthine oxidoreductase (XOR) with an IC50 value of 7.2 nM. This compound exhibits significant hypouricemic effects in murine models, making it a valuable tool for research into disorders related to uric acid metabolism. It is suitable for investigating the role of XOR in conditions such as gout and oxidative stress-related diseases. -
Xanthine Oxidase Inhibitor
Xanthine oxidase-IN-19 is a potent inhibitor of xanthine oxidase (XO) with an IC50 of 0.2 μM. This compound effectively reduces serum uric acid levels in models of acute hyperuricemia, making it valuable for research into hyperuricemia-related conditions. Xanthine oxidase-IN-19 serves as a useful tool for studying the biochemical and physiological impacts of XO inhibition. -
Xanthine Oxidase Inhibitor
Xanthine oxidase-IN-20 is a highly potent inhibitor of xanthine oxidase, exhibiting an IC50 of 1.7 nM. This compound demonstrates significant efficacy in reducing serum uric acid levels in acute hyperuricemia models in both mice and rats. With a favorable safety profile, Xanthine oxidase-IN-20 is suitable for research focusing on hyperuricemia and gout. -
Xanthine Oxidase Inhibitor
Ilexoside O is a triterpene saponin that functions as a xanthine oxidase inhibitor. Isolated from the roots of Ilex pubescens, it demonstrates moderate inhibitory activity against xanthine oxidase with an IC50 value of 53.05 μM. This compound is relevant for studies investigating oxidative stress and related metabolic pathways. Its application may extend to research on conditions such as gout and hyperuricemia. -
Xanthine Oxidase Inhibitor
Tricetin 3',4',5'-trimethyl ether, a selective xanthine oxidase inhibitor, exhibits competitive inhibition with an IC50 value of 0.51 μM and a Ki of 0.37 μM. Derived from the flowers of Chrysanthemum sinensea, this flavone glucoside demonstrates significant biological activity relevant to oxidative stress and inflammation research. It is a valuable tool for studies exploring the modulation of purine metabolism and the potential therapeutic implications in conditions associated with elevated xanthine oxidase activity. -
Xanthine Oxidase Inhibitor
Fraxamoside is a competitive inhibitor of xanthine oxidase, demonstrating an IC50 value of 16.1 μM and a Ki of 0.9 μM. This compound effectively modulates the activity of xanthine oxidase, an enzyme involved in purine metabolism and reactive oxygen species production. Fraxamoside is primarily utilized in research focused on conditions associated with elevated uric acid levels, oxidative stress, and inflammation. -
Xanthine Oxidase Inhibitor
Aurantiamide benzoate acts as a potent inhibitor of xanthine oxidase, exhibiting an IC50 value of 70 μM. This natural product is derived from the tropical medicinal plants Cunila spicata and Hyptis fasciculata. Its inhibition of xanthine oxidase suggests potential applications in the treatment of conditions associated with elevated uric acid levels, such as gout and certain cardiovascular diseases. -
Xanthine Oxidoreductase Inhibitor
Xanthine oxidoreductase-IN-3 is a potent inhibitor of xanthine oxidoreductase (XOR), characterized by an IC50 of 26.3 nM. This compound is primarily utilized in research focused on acute hyperuricemia, demonstrating its potential to modulate uric acid levels effectively. Its oral bioavailability makes it a valuable tool in exploring therapeutic approaches for conditions associated with elevated uric acid. -
XO Inhibitor
Xanthine oxidase-IN-5 is a potent and orally active inhibitor of xanthine oxidase (XO), exhibiting an IC50 value of 0.70 μM. This compound demonstrates favorable ligand efficiency (LE) and lipophilic ligand efficiency (LLE) values of 0.33 and 3.41, respectively. Xanthine oxidase-IN-5 has shown significant hypouricemic effects in hyperuricemic rat models, making it a valuable tool for research into conditions related to elevated uric acid levels. -
Xanthine Oxidase Inhibitor
Forsythoside F is a potent inhibitor of xanthine oxidase, an enzyme implicated in the production of uric acid. It exhibits antihyperuricemic properties, making it relevant for research focused on conditions such as gout and other disorders associated with elevated uric acid levels. This compound is valuable for studies investigating the modulation of uric acid metabolism and related physiological pathways. -
XOD Inhibitor
Xanthine oxidase-IN-17 is a selective inhibitor of xanthine oxidase (XOD), demonstrating an IC50 of 298 nM and a Ki of 167 nM. By inhibiting XOD, it effectively reduces the generation of superoxide radicals and decreases uric acid production. This compound exhibits no cytotoxic effects on AML-12 hepatocyte cells and is valuable for research addressing hyperuricemia and gout. -
Xanthine Oxidase Inhibitor
Eupatoriochromene is a chromene compound that serves as an inhibitor of xanthine oxidase (XO). By inhibiting XO activity, it has potential implications in the management of conditions associated with elevated uric acid levels, such as gout. This compound can be utilized in research applications focused on purine metabolism and oxidative stress. -
XOD Inhibitor
Xanthine oxidase-IN-8 (Icarisids J) is a selective inhibitor of xanthine oxidase (XOD) with an IC50 value of 29.71 μM. This compound demonstrates significant activity in reducing uric acid production, making it useful for studying conditions associated with hyperuricemia, such as gout. Its inhibitory effects on XOD can assist in elucidating the enzyme's role in various metabolic pathways and potential therapeutic interventions. -
Xanthine Oxidase Inhibitor
Angexostat is a potent xanthine oxidase inhibitor, effectively blocking its enzymatic activity. With demonstrated high permeability, Angexostat inhibits CYP2C9 with an IC50 of 18.1 μM. This compound is valuable in research focused on xanthine oxidase-related conditions, including hyperuricemia and gout, providing insights into potential therapeutic strategies. -
XOR Inhibitor
Xanthine oxidoreductase-IN-4 is a potent inhibitor of xanthine oxidoreductase (XOR) with an IC50 value of 29.3 nM. This compound demonstrates significant inhibitory activity, making it a valuable tool for investigating metabolic disorders associated with hyperuricemia. Xanthine oxidoreductase-IN-4 can facilitate research aimed at understanding the role of XOR in uric acid metabolism and related conditions. -
Xanthine Oxidase Inhibitor
Xanthine oxidase-IN-10 is a potent inhibitor of xanthine oxidase, an enzyme involved in the production of reactive oxygen species. By inhibiting this enzyme, Xanthine oxidase-IN-10 demonstrates potential anti-inflammatory and antioxidant properties. This reagent is valuable for research applications in understanding gout, hyperuricemia, and oxidative stress-related conditions.
